/

CareDx, Inc

CDNA US

CDNA USCareDx, Inc

United States Composite

7.56

USD

- -

-3.54EPS Dil.

-2.14P/E

389.36MMarket Cap

CareDx, Inc

CDNA

(United States Composite)

Recent

price

7.56

P/E

ratio

-2.14

div

yld

- -

ROIC.AI

Legends:

Stock price

1.33

Beta (1.0 Market)

% total return 04/27

Stock

S&P500

YTD

30.33

- -

-87.42

- -

-64.27

- -

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

2.77

3.00

4.69

2.37

2.46

2.07

2.15

3.01

4.13

5.67

6.03

5.21

- -

-0.69

-0.48

0.13

-1.16

-2.39

-2.38

-1.31

-0.52

-0.40

-0.59

-1.44

-3.54

- -

-0.26

-0.09

-0.70

-0.92

-1.03

-0.62

-0.32

-0.17

0.43

-0.89

-0.99

-0.53

- -

-21.24

-21.72

-13.50

-14.54

-9.99

-9.30

-7.53

-7.85

-7.13

-7.24

-8.60

-13.17

- -

-19.97

-20.44

1.92

0.91

-1.28

-1.77

1.22

0.70

4.24

7.16

6.54

3.40

- -

127

192

296

322

280

- -

-11.45

-3.88

0.04

-42.84

-60.96

-37.94

-20.35

-19.31

-9.22

-10.03

-24.00

-37.36

- -

-5

-4

-14

-39

-55

-47

-22

-19

-31

-77

-190

- -

-24.74

-16.03

2.86

-48.70

-97.14

-114.79

-61.06

-17.29

-9.74

-10.34

-23.81

-67.88

- -

-14

-16

204

356

312

236

- -

-147

-151

-6

278

466

431

261

- -

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

459

379

618

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

361

345

314

Cash, Cash Equivalents & STI

283

268

235

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

31.64%

33.20%

-13.04%

Net Income, GAAP

-212.15%

-58.29%

-146.75%

Free Cash Flow

-113.98%

-129.86%

45.28%

Total Cash Common Dividend

- -

Total Equity

-181.28%

40.92%

-39.44%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

296

2022

322

2023

280

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.01

-0.04

-0.23

-0.31

-0.59

2022

-0.37

-0.41

-0.32

-0.34

-1.44

2023

-0.44

-0.46

-0.43

-2.21

-3.54

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Company News

Yahoo
8 days ago
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Yahoo
10 days ago
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
Zacks
10 days ago
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
Yahoo
11 days ago
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
Yahoo
18 days ago
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
Yahoo
a month ago
How CareDx (CDNA) Stock Stands Out in a Strong Industry
Zacks
a month ago
How CareDx (CDNA) Stock Stands Out in a Strong Industry
Yahoo
2 months ago
CareDx Appoints Bryan Riggsbee to Its Board of Directors
Tipranks
2 months ago
CareDx Hold Rating: Balancing Modest Growth Prospects with Operational Uncertainties

Business: CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

- -

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

2.77

3.00

4.69

2.37

2.46

2.07

2.15

3.01

4.13

5.67

6.03

5.21

- -

-0.69

-0.48

0.13

-1.16

-2.39

-2.38

-1.31

-0.52

-0.40

-0.59

-1.44

-3.54

- -

-0.26

-0.09

-0.70

-0.92

-1.03

-0.62

-0.32

-0.17

0.43

-0.89

-0.99

-0.53

- -

-21.24

-21.72

-13.50

-14.54

-9.99

-9.30

-7.53

-7.85

-7.13

-7.24

-8.60

-13.17

- -

-19.97

-20.44

1.92

0.91

-1.28

-1.77

1.22

0.70

4.24

7.16

6.54

3.40

- -

127

192

296

322

280

- -

-11.45

-3.88

0.04

-42.84

-60.96

-37.94

-20.35

-19.31

-9.22

-10.03

-24.00

-37.36

- -

-5

-4

-14

-39

-55

-47

-22

-19

-31

-77

-190

- -

-24.74

-16.03

2.86

-48.70

-97.14

-114.79

-61.06

-17.29

-9.74

-10.34

-23.81

-67.88

- -

-14

-16

204

356

312

236

- -

-147

-151

-6

278

466

431

261

- -